Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
Multi-Modality Imaging and Correlative Studies in Patients With Leukemia
City of Hope Medical Center
74 participants
Feb 15, 2018
INTERVENTIONAL
Conditions
Summary
This clinical trial investigates multi-modality imaging and collection of biospecimen samples in understanding bone marrow changes in patients with acute myeloid leukemia undergoing total body irradiation (TBI) and chemotherapy. Using multi-modality imaging and collecting biospecimen samples may help doctors know more about how TBI and chemotherapy can change the bone marrow.
Eligibility
Inclusion Criteria7
- Cohort TMLI+FLT: AML patients eligible for and enrolling on COH 14012 or IRB 17505 that agree to participate in optional FLT PET imaging
- Note: patients enrolling on IRB 19518 cannot enroll onto this cohort, but they may enroll on Cohort TMLI (below)
- Cohort TMLI: AML or ALL patients eligible for and enrolling on COH 14012, IRB 17505 or IRB 19518
- Cohort TBI: First or second remission AML or ALL patients that will receive TBI (13.2 Gy) plus chemotherapy (etoposide \[VP16\] 60 mg/kg or cyclophosphamide \[Cy\] 60 mg/kg for two days) as part of their standard of care
- Cohort TBI: Documented written informed consent of participant
- Cohort TBI: Age \>= 18 to =\< 60 years
- Cohort TBI: Patients who have not received a prior transplant
Interventions
Undergo collection of bone marrow and blood samples
Undergo DECT
Undergo FLT PET
Correlative studies
Undergo water-fat MRI
Undergo FLT PET
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03422731